TACOS 2022 Fall Conference Continuing Education

Eliminating Disparities in Access to Quality Care in Patients with Gastric and Esophagogastric Junction Adenocarcinoma

November 12, 2022 | 8:55 - 9:55 AM MT

Point Hilton Tapatio Cliffs Resort

11111 North 7th St.

Phoenix, AZ 85020

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported by an educational grant from Lilly.

Target Audience

Physicians, NPs, PAs, Nurses.

Learning Objectives

At the end of this educational activity, participants should be able to:

Apply evidence-based treatment selection for patients with unresectable, locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
Employ strategies for the optimal management of treatment-related adverse events experienced by patients treated for unresectable, locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
Implement solutions for improving care coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with unresectable, locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
Explore patient-centric interventions for promoting guideline-concordant treatment for underserved racial/ethnic minority patient populations with unresectable, locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.

Agenda

Welcome, pre-activity assessment, and introductions

Case Discussions

Faculty will present 2-3 clinical case scenarios, and initiate discussion on the optimal management of unresectable, locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma. Faculty will give evidence-based rationales for treatment choices at each decision point. Discussion points will include:

Patient-centric treatment selection
Communication and coordination between the oncologist and other clinicians on the cancer care team
Adverse event monitoring and management
Patient engagement
Access to care disparities for underserved patients

Discussion and Q&A

Faculty

Tomislav Dragovich, MD, PhD
Professor [Adj] of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center; Chief, Division of Clinical Research, Banner MD Anderson Cancer Center, AZ

Tonya Kinsinger, APRN
Oncology Nurse Practitioner, Banner MD Anderson Cancer Center, AZ

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE Logo This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

Name of Faculty or Presenter/Planner	Reported Financial Relationship

Tomislav Dragovich, MD, PhD	Nothing to disclose
Tonya Kinsinger, APRN	Nothing to disclose

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

Name of Planner/Manager/Reviewer	Reported Financial Relationship

Tomislav Dragovich, MD, PhD	Nothing to disclose
Holly M. Hampe, DSc, RN, MHA, MRM, CPHQ	Nothing to disclose
Tonya Kinsinger, APRN	Nothing to disclose
Sandra Megally	Nothing to disclose
Robert Mocharnuk, MD	Common stock: Merck
Dee Morgillo, MEd., MT (ASCP) CHCP	Nothing to disclose

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

Attend/participate in the educational activity and review all course materials.
Complete the CE Declaration form online by 11:59 PM ET on December 12, 2022. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.
Upon successful completion of the online form, your statement of completion will be presented to you to print. Pharmacists: your record will be automatically uploaded to CPE Monitor.